Innoviva (INVA) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Innoviva (INVA) overview

Innoviva (INVA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 411m and operating profit of USD 164m; the year-end share price was 19.99 USD and market capitalisation was USD 1,492m. Innoviva is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Innoviva's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 1,173mFY 2025
Share price19.99 USDFY 2025 year end
RevenueUSD 411mFY 2025
Operating profitUSD 164mFY 2025
Net earningsUSD 271mFY 2025
Market capitalisationUSD 1,492mFY 2025 year end

About Innoviva

Innoviva is a biopharmaceutical company with respiratory royalty interests, a critical care and infectious disease business, and other healthcare investments. It receives royalties from GSK on RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Its marketed hospital-focused products include treatments for shock, bacterial pneumonia, complicated intra-abdominal infections, bloodstream and skin infections, and gonorrhea. It also holds a stake in Armata Pharmaceuticals.

Generate the Innoviva report

Innoviva is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Innoviva and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Innoviva

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.